TrianglePD-L1 t-haNK cells (NCT06161545)
PD-L1 t-haNK cells trial for Stage II Squamous Cell Carcinoma of the Head and Neck (NCT06161545). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults aged 18–120 with untreated stage II–IV head-and-neck squamous cancer scheduled for surgery. Oropharyngeal tumors must be p16-negative; distant spread excludes participation.
The idea: pembrolizumab and N-803 stimulate immune defenses before surgery. A later group also receives five infusions of PD-L1 t-haNK cells to attack cancer. Assignment is sequential, not random. Biopsies before and after treatment help assess tumor response.
This phase 2 study plans 40 patients. NCI’s Charalampos Floudas leads it at NIH in Bethesda, the single recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.